<DOC>
	<DOCNO>NCT00502294</DOCNO>
	<brief_summary>To compare efficacy visilizumab 5 mcg/kg/day administer intravenously ( IV ) Days 1 2 placebo subject IVSR-UC .</brief_summary>
	<brief_title>A Phase 3 , Randomized , Double-Blind , Placebo-Controlled , Multicenter Study Visilizumab Subjects With Intravenous Steroid-Refractory Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Males female , 18 year age old . Diagnosis UC verify endoscopy within 60 month prior consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Ulcerative Colitis , UC , Intravenous Steroid-Refractory Ulcerative Colitis , IVSR-UC</keyword>
</DOC>